AS per file enclosed.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies reported strong FY2026 results with standalone revenue from operations of Rs. 768.73 crore, up 19.3% from Rs. 644.47 crore in FY2025. Net profit jumped 89% to Rs. 99.31 crore from Rs. 52.55 crore. Consolidated revenue was Rs. 769.60 crore with net profit of Rs. 102.78 crore, representing 127% PAT growth over the prior year. EBITDA margin improved significantly. The board recommended a final dividend of Rs. 10 per share (100%) subject to shareholder approval at the 37th AGM scheduled for August 20, 2026. Statutory auditors J.K. Jain & Associates issued an unmodified (clean) opinion on both standalone and consolidated financial statements.
The company demonstrated robust double-digit revenue growth and exceptional profit expansion, indicating strong operational performance and cost efficiency. The clean audit opinion and dividend declaration are positive signals for shareholders. The stock may see positive reaction given the strong profitability growth.